|
摘要：
|
|
摘要：目的 评价直接抗病毒药物（direct-acting antiviral agent，DAA）对HCV感染相关性肝细胞肝癌
（hepatocellular carcinoma，HCC）发生或复发的影响。方法 通过计算机检索PubMed、EMBASE、
Cochrane Library、中国期刊全文数据库及万方数据库中2013年1月1日至2018年3月31日关于DAA对
HCV感染相关性HCC发生或复发的临床随机对照研究，检索词为HCV、DAA、HCC发生和HCC复
发，采用RevMan5.3和Stata12.0软件进行Meta分析。结果 HCC发生组共纳入7篇文献，DAA组共21645
例患者，其中341例发生HCC；非DDA组共14875例，其中405例发生HCC。Meta分析结果显示，DAA
类药物可降低HCV感染者HCC的发生率（OR = 0.60，95% CI：0.52～0.70，P ＜ 0.00001）。HCC复
发组共纳入9篇文献，DAA组共806例患者，其中418例HCC复发；非DAA组共598例患者，其中294例
HCC复发。Meta分析结果显示，DAA类药物可降低HCV感染者HCC的复发率（OR = 0.73，95%CI：
0.57～0.94，P = 0.01）。结论 DAA治疗可降低HCV感染相关HCC的发生和复发。
|
|
Abstract: Objective To evaluate the effects of direct-acting antiviral agent (DAA) on the occurrence or recurrence
of hepatocellular carcinoma (HCC) in patients infected with hepatitis C virus (HCV). Methods PubMed, EMBASE,
Cochrane Library, China Journal Full-text Database (CNKI), and Wanfang Database were searched by computer to
retrieve a randomized controlled trial of DAA on the occurrence or recurrence of HCC in patients infected with HCV
from January 1st, 2013 to March 31st, 2018. The key words contained hepatitis C virus, direct-acting antiviral, HCC
occurrence, HCC recurrence. Meta analysis was performed by RevMan 5.3 and Stata 12.0 software. Results A total
of 7 articles were included in HCC group. There were 21445 cases in DAA group, among whom 341 cases developed
HCC; there were 14875 cases in non-DDA group, among whom 405 cases developed HCC. Meta-analysis showed
that DAA can reduce the incidence of HCC in patients infected with HCV (OR = 0.60, 95%CI: 0.52～0.70, P ＜
0.00001). A total of 9 articles were included in HCC recurrence group. There were 806 cases in DAA group, among
whom 418 cases recurred HCC; there were 598 cases in non-DAA group, among whom 294 cases recurred HCC .
Meta-analysis showed that DAA can reduce the recurrence rate of HCC (OR = 0.73, 95%CI: 0.57～0.94, P = 0.01).
Conclusion DAA can reduce the incidence and recurrence rate of HCV-related HCC.
|
|
基金项目：
|
|
|
|
作者简介：
|
|
|
|
参考文献：
|
|
|
|
服务与反馈：
|
|
【文章下载】【加入收藏】
|
|
|
|